RivelleseAA, RiccardiG, VaccaroO. Cardiovascular risk in women with diabetes. Nutr Metab Cardiovasc Dis, 2010; 20:474–480.
4.
Schenck-GustafssonK. Risk factors for cardiovascular disease in women. Maturitas, 2009; 63:186–190.
5.
LombardiM, MercuroG, FiniM, RosanoGM. Gender-specific aspects of treatment of cardiovascular risk factors in primary and secondary prevention. Fundam Clin Pharmacol, 2010; 24:699–705.
6.
Rich-EdwardsJW, McElrathTF, KarumanchiSA, SeelyEW. Breathing life into the life course approach: Pregnancy history and cardiovascular disease in women. Hypertension, 2010; 56:331–334.
7.
BilhartzTD, BilhartzPA, BilhartzTN, BilhartzRD. Making use of a natural stress test: Pregnancy and cardiovascular risk. J. Womens Health, 2011; 20:695–701.
8.
RomundstadPR, MagnussenEB, SmithGD, VattenLJ. Hypertension in pregnancy and later cardiovascular risk: Common antecedents?Circulation, 2010; 122:579–584.
9.
MagnussenEB, VattenLJ, SmithGD, RomundstadPR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol, 2009; 114:961–970.
DuckittK, HarringtonD. Risk factors for pre-eclampsia at antenatal booking: Systematic review of controlled studies. BMJ., 2005; 330:565.
12.
RidkerPM, BuringJE, RifaiN, CookNR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA, 2007; 297:611–619.
13.
KumruS, GodekmerdanA, KutluS, OzcanZ. Correlation of maternal serum high-sensitive C-reactive protein levels with biochemical and clinical parameters in preeclampsia. Eur J Obstet Gynecol Reprod Biol, 2006; 124:164–167.
14.
HwangHS, KwonJY, KimMA, ParkYW, KimYH. Maternal serum highly sensitive C-reactive protein in normal pregnancy and pre-eclampsia. Int J Gynaecol Obstet, 2007; 98:105–109.
15.
SharmaRK, SinghVN, ReddyHK. Thinking beyond low-density lipoprotein cholesterol: Strategies to further reduce cardiovascular risk. Vasc Health Risk Manag, 2009; 5:793–799.
16.
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Panel (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation, 2002; 106:3143–3421.
17.
TothPP. The impact of HDL-C elevation on patient outcomes: What do the data tell us? MedscapeCME Cardiol, September7, 2010. www.medscape.org/viewarticle/727469.
18.
StaffAC, DechendR, PijnenborgR. Learning from the placenta: Acute atherosis and vascular remodeling in preeclampsia—Novel aspects for atherosclerosis and future cardiovascular health. Hypertension, 2010; 56:1026–1034.
19.
WiznitzerA, MayerA, NovackVet al.Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: A population-based study. Am J Obstet Gynecol, 2009; 201:482.e1–8.
20.
U.S. Preventive Services Task Force (USPSTF). Screening for lipid disorders in adults: Summary of recommendations, 2008. www.ahrq.gov/clinic/USpstf/uspschol.htm. 2009 December 5.
21.
Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive summary. www.nhlbi.nih.gov/guidelines/cholesterol/atp_iii.htm. 2009 December 5.
22.
KuklinaEV, YoonPW, KeenanNL. Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999–2006. Ann Fam Med, 2010; 8:327–333.